EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

7. Can a clinic buy compounded GLP-1 medicines for office use?

Dose Diligence research deskSection 01 · Page 7 of 34Last updated 17 Nov 2026

A non-patient-specific office-stock arrangement requires a different analysis from named-patient dispensing. FDA’s 503A prescription guidance directs non-patient-specific compounded supply toward qualifying outsourcing facilities, subject to applicable requirements. (fda.gov)

That does not establish an available 503B semaglutide or tirzepatide route. Ingredient eligibility and copying restrictions still need to be satisfied; FDA’s April 2026 proposal explains the separate shortage-list and clinical-need-list conditions for bulk compounding. (fda.gov)

Before considering office stock, specify:

  • Whether the medicine is for an already identified patient or future unidentified patients.
  • Whether the clinic will administer it, dispense it for home use or transfer it elsewhere.
  • Who owns it and when ownership changes.
  • The producing facility, ingredients and legal justification.
  • Applicable state permissions and storage controls.

A package delivered to a clinic address should not be classified as unrestricted clinic inventory merely because it arrived there. Have counsel and pharmacy leadership classify the arrangement before ordering.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/media/97347/download?utm_source=openai
  2. fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list?utm_source=openai
Section sources →